论文部分内容阅读
目的探讨康妇消炎栓联合氧氟沙星、甲硝唑治疗慢性盆腔炎的临床效果。方法选取大余县人民医院妇产科2013年1月—2014年10月收治的慢性盆腔炎患者65例,随机分为对照组32例和观察组33例。对照组患者予以氧氟沙星+甲硝唑静脉滴注治疗,观察组患者在对照组基础上给予康妇消炎栓治疗,两组患者均持续治疗2个疗程。观察比较两组患者的临床疗效,治疗前后血清炎性因子(白介素1β、肿瘤坏死因子α、白介素10)水平变化情况及治疗期间不良反应发生情况。结果观察组患者治疗总有效率高于对照组(P<0.05)。治疗前,两组患者血清白介素1β、肿瘤坏死因子α、白介素10水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者血清白介素1β、肿瘤坏死因子α水平低于对照组,白介素10水平高于对照组(P<0.05)。观察组患者不良反应发生率低于对照组(P<0.05)。结论康妇消炎栓联合氧氟沙星、甲硝唑治疗慢性盆腔炎效果明显,可有效抑制血清白介素1β、肿瘤坏死因子α的分泌,提高白介素10表达,且不良反应少。
Objective To investigate the clinical effect of Kangfu anti-inflammatory suppository combined with ofloxacin and metronidazole in the treatment of chronic pelvic inflammatory disease. Methods 65 cases of chronic pelvic inflammatory disease admitted from January 2013 to October 2014 in Dayu County People’s Hospital were randomly divided into control group (32 cases) and observation group (33 cases). Patients in the control group were treated with ofloxacin and metronidazole intravenously. Patients in the observation group were treated with Kangfu anti-inflammatory suppository on the basis of the control group. Both groups were treated with 2 courses of continuous treatment. The clinical efficacy of the two groups were observed and compared. The changes of serum inflammatory factors (interleukin 1β, tumor necrosis factor α and interleukin 10) before and after treatment and the incidence of adverse reactions during the treatment were observed and compared. Results The total effective rate of observation group was higher than that of control group (P <0.05). Before treatment, serum interleukin-1β, tumor necrosis factor-α and interleukin-10 levels were not significantly different between the two groups (P> 0.05). After treatment, the levels of serum interleukin-1β and tumor necrosis factor-α in the observation group were lower than those in the control group , Interleukin 10 levels higher than the control group (P <0.05). The incidence of adverse reactions in observation group was lower than that in control group (P <0.05). Conclusion Kangfu anti-inflammatory suppository combined with ofloxacin and metronidazole has obvious effect in treating chronic pelvic inflammatory disease, which can effectively inhibit the secretion of serum interleukin-1β and tumor necrosis factor-α and increase the expression of interleukin-10 with less adverse reactions.